Pluristem Therapeutics Inc (PSTI)

[Auto1]

CMS WILL NOT cover this if the primary indication is MWD. PERIOD. PSTI IMHO made a COLOSSAL mistake when they did not design and power this study for amputation as the primary endpoint.

Had they done so, I believe this PII would have propelled a priority and expedited review and approval by eoy 2019.

Instead, as was stated earlier, we are looking at 36mos with follow up.

That is a HUGE miss. Sorry, but Leadership is where success and failure rests .